Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Team Hewins LLC

Team Hewins LLC decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,084 shares of the medical instruments supplier’s stock after selling 124 shares during the period. Team Hewins LLC’s holdings in Becton, Dickinson and Company were worth $268,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Ontario Teachers Pension Plan Board lifted its position in Becton, Dickinson and Company by 3.8% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock valued at $451,641,000 after purchasing an additional 68,509 shares during the period. Jennison Associates LLC lifted its position in Becton, Dickinson and Company by 4.9% in the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after purchasing an additional 18,786 shares during the period. Sapient Capital LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at about $1,295,000. Vest Financial LLC lifted its position in Becton, Dickinson and Company by 27.5% in the fourth quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock valued at $25,115,000 after purchasing an additional 22,207 shares during the period. Finally, Norden Group LLC lifted its position in Becton, Dickinson and Company by 2,086.7% in the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after purchasing an additional 49,559 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BDX shares. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 27th. Barclays increased their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday, May 6th. Evercore ISI dropped their target price on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Citigroup dropped their target price on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and an average price target of $280.14.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,615 shares of company stock worth $2,033,381. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX traded up $1.41 during mid-day trading on Thursday, reaching $225.28. 820,997 shares of the company’s stock were exchanged, compared to its average volume of 1,427,639. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The company has a 50-day simple moving average of $233.34 and a two-hundred day simple moving average of $237.11. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $287.32. The company has a market cap of $65.11 billion, a price-to-earnings ratio of 49.31, a PEG ratio of 1.97 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period last year, the company posted $2.86 EPS. The company’s revenue was up 4.6% on a year-over-year basis. On average, sell-side analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Monday, June 10th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a yield of 1.69%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.